Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Iridina is a brand of ophthalmic products primarily marketed for the relief of eye irritation, redness, burning, excessive tearing, and sensitivity to light. The most common formulation is Iridina Due®, which contains naphazoline nitrate or naphazoline hydrochloride as its active ingredient—a sympathomimetic vasoconstrictor that acts on alpha-adrenergic receptors in ocular arterioles to reduce congestion and redness[1][5][6]. Some variants (such as "Iridina Antistaminico") also contain tonzilamine hydrochloride (an antihistamine) for allergic conjunctivitis[4][8]. Other formulations under the Iridina name include lubricating drops with sodium hyaluronate for dry eyes[7][9]. The primary mechanism of action is vasoconstriction via alpha-adrenergic receptor agonism; antihistaminic action may be present in combination products.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iridina.